Cyxone concludes IBD pilot study with its cyclotide
Cyxone AB (publ) announced today that the company’s second and last phase of the pilot study in inflammatory bowel disease (IBD) with its cyclotide technology has been concluded. The results add to the growing body of evidence around the cyclotide technology, deepening the understanding of this natural plant protein.
The pilot study comprised two consecutive phases, testing the cyclotide in two different animal models, with the purpose of investigating the effect of cyclotides against inflammatory bowel disease (IBD). Although the clinically induced inflammation of the inner lining of the colon was not reduced, the data did show indicative results of an anti-inflammatory effect exhibited through reduced size of the lymph nodes associated with the colon, reduction of CD3 positive T-cells and decreased Lipocalin-2 levels.
“It is, as always, disappointing to not only get positive results. But although this pilot study failed to show desired effect in the colon, the findings supporting the cyclotide’s anti-inflammatory effect is promising and are also aligned with the effects seen in multiple sclerosis (MS) models,” said Kjell G. Stenberg, CEO of Cyxone. “Based on these results, we have concluded that our cyclotide technology program will, at this time, maintain its focus of advancing the development of T20K for the treatment of MS.”
This pilot study was prompted by the earlier discovery of the cyclotide’s ability to inhibit a key factor for inflammatory diseases, IL-2, and its accumulation in the intestine and spleen, the organs considered to be involved in IBD. Originally, research into the disease was initiated based on an inquiry by a pharmaceutical company that had observed Cyxone’s research for its T20K in MS.
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase 2 program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.